about
E2F1 up-regulates the expression of the tumour suppressor axin2 both by activation of transcription and by mRNA stabilisationEstrogen receptor {beta}1 expression is regulated by miR-92 in breast cancerExpression of axin2 is regulated by the alternative 5'-untranslated regions of its mRNACross-talk between pRb/E2F and Wnt/beta-catenin pathways: E2F1 induces axin2 leading to repression of Wnt signalling and to increased cell deathNeoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancerChemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy.MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion.PSMD9 expression predicts radiotherapy response in breast cancer.Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cellsResponse to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer.Prognostic microRNAs in high-grade glioma reveal a link to oligodendrocyte precursor differentiation.Down-Regulation of miR-92 in Breast Epithelial Cells and in Normal but Not Tumour Fibroblasts Contributes to Breast CarcinogenesisRegulation of gene expression by alternative untranslated regions.Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer.Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting.In situ and invasive lobular neoplasia of the breast.Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancerCombined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activityDifferential regulation of oestrogen receptor β isoforms by 5' untranslated regions in cancerTargeting glucose metabolism: an emerging concept for anticancer therapy.Surgery induced immunosuppression.Circulating tumour cells in breast cancer: Prognostic indicators, metastatic intermediates, or irrelevant bystanders? (Review).The roles of microRNAs in sarcomas.Intra-operative tumour detection and staging in colorectal cancer surgery.CEA-targeted nanoparticles allow specific in vivo fluorescent imaging of colorectal cancer models.Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signatureRegulation of estrogen receptor β1 expression in breast cancer by epigenetic modification of the 5' regulatory region.Expression of oestrogen receptor beta isoforms is regulated by transcriptional and post-transcriptional mechanisms.Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.Regulation of estrogen receptor beta by 5' untranslated regions in breast carcinogenesis.Stromal fibroblasts with nuclear β-catenin are present within breast tumours and increase proliferation and invasion of epithelial breast cancer cells.Investigation of immunoregulatory mechanisms relating to poor surgical wound healing and breast cancer recurrence.CIP2A expression predicts recurrences of tamoxifen-treated breast cancer.Epithelial-mesenchymal interactions in breast cancer: evidence for a role of nuclear localized β-catenin in carcinoma-associated fibroblasts.Clinical importance of estrogen receptor beta isoforms in breast cancer.Mathematical and biological modelling of RNA secondary structure and its effects on gene expression.Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours.Regulation of axin2 expression at the levels of transcription, translation and protein stability in lung and colon cancer.MicroRNA-92 targets the 3' untranslated region of ERβ1 mRNA and post-transcriptionally regulates its expression in breast cancer.Differential Expression of MicroRNAs in Breast Cancers from Four Different Ethnicities
P50
Q24298031-0152368D-9FE3-440B-86D8-CBA89593651AQ24595552-C9EA5027-169B-42AE-BAAA-3E4AD65BA434Q28299323-75B536FB-A2AE-45AC-91AE-5BC36AE9B61FQ28577344-6CD3901A-BE87-41BB-8EAF-AAE1AF54E5A9Q28706276-87804FDB-5CF9-49EB-842D-9CDB95C51676Q30403036-B586EE79-7F11-4DE9-9670-67AFE3C56DA3Q33648427-25881421-D3C0-48DC-9ACE-1A3387E1EB9BQ34501422-A10605E2-71A1-4D1A-BF9F-615FB571F4CFQ34619744-0FDA0211-BEC1-4486-B638-DECAA40E8A8BQ34660064-6B015CD8-47BE-41AF-AFBD-319A6889C809Q35376154-A8F0BB16-D9A9-424E-ADFA-42C7977D2D4FQ35799412-392E748B-1DD0-4B3B-8683-499CA821D7E5Q36375512-2144B3F5-264C-43C6-8154-C3A49D13C01FQ36503756-7BC199D6-5BED-49D9-9582-1C716CBC8951Q36671897-8A495C50-35EE-4A5A-93D1-915757CF39E6Q37048769-4095671B-DFC7-4AF0-9BB4-EC45E279666CQ37151073-12DA831C-3233-4065-B10B-53012BC7E9D1Q37222629-D61F3A4A-8280-492D-A36A-FE650D77DAE9Q37294996-5D8379A6-8AB3-4C44-8CA6-1D7F2F623898Q37784126-894DCE5A-5963-4A99-B23F-569713F65229Q37825004-20CAF77D-386D-480C-92BD-7342D7F47A8AQ37863503-B4B6B58C-63B0-456F-8851-674A5F3D19A5Q38001369-A4B18C8C-23FD-4D17-B188-B7B9A81BE6A1Q38008038-6E45BE04-1894-412F-9911-3529031AA9DCQ38908263-A8CA18A0-81FF-4B23-B09C-040B837E8568Q38929512-2C15627D-4258-4BE6-AD74-0D1A2F795A77Q39091753-FF979710-5208-4E98-B71A-97F1153DDF6FQ39704713-49ED5F36-5923-473E-B0A7-E5408E7330AFQ46433363-4B17E8A7-2C4F-4C76-ABF6-3B0EBAECD117Q46942634-C9979FB7-CE0A-4F8F-9D92-820AC21594A5Q46942957-2288ADF5-9BA8-4BFD-91E4-19C8EBBCA344Q46943624-1C06BDF3-B3C8-4D2B-AE37-1620C7EFA895Q47649534-171D1A17-95E3-4C16-AEAF-C91B333F5642Q50509631-4BEE9830-CBE9-47C6-8148-2E0FD85C8CE3Q50614109-5A7A9573-3432-4017-855D-B037265E21D4Q51949073-A82A6C52-FCC7-4FC7-83DF-A9A3836DE3B3Q52843051-D4225777-247A-44D6-B764-05BC0CC3B88BQ53358188-5E18774F-8AD0-4278-97B2-56AC68DE30A8Q55561913-9014D5B5-C660-4080-81C4-BEA3FAACE294Q56834876-96494138-D159-4900-934A-E85A6CAF2C7F
P50
description
hulumtues
@sq
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Thomas A Hughes
@ast
Thomas A Hughes
@br
Thomas A Hughes
@ca
Thomas A Hughes
@cs
Thomas A Hughes
@cy
Thomas A Hughes
@da
Thomas A Hughes
@de
Thomas A Hughes
@de-at
Thomas A Hughes
@de-ch
Thomas A Hughes
@en
type
label
Thomas A Hughes
@ast
Thomas A Hughes
@br
Thomas A Hughes
@ca
Thomas A Hughes
@cs
Thomas A Hughes
@cy
Thomas A Hughes
@da
Thomas A Hughes
@de
Thomas A Hughes
@de-at
Thomas A Hughes
@de-ch
Thomas A Hughes
@en
prefLabel
Thomas A Hughes
@ast
Thomas A Hughes
@br
Thomas A Hughes
@ca
Thomas A Hughes
@cs
Thomas A Hughes
@cy
Thomas A Hughes
@da
Thomas A Hughes
@de
Thomas A Hughes
@de-at
Thomas A Hughes
@de-ch
Thomas A Hughes
@en
P1053
O-8031-2015
P106
P21
P31
P3829
P496
0000-0003-1169-3386